Recently, a multi-biomarker test (MBT) evaluating αPGL-I IgM, IP-10, CRP, S100A12, and ApoA1 was successfully used to discriminate patients with MB and PB leprosy from control individuals in high and low leprosy endemic areas.13 This evidence concerns the gene CXCL10 and leprosy.